Seaport Global Securities reaffirmed their buy rating on shares of Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) in a research note published on Friday, March 16th. Seaport Global Securities currently has a $11.00 price objective on the biotechnology company’s stock.
Other equities research analysts also recently issued reports about the company. BidaskClub downgraded Isotechnika Pharma from a hold rating to a sell rating in a research report on Wednesday, January 31st. Zacks Investment Research raised Isotechnika Pharma from a strong sell rating to a hold rating in a research report on Monday, January 22nd. ValuEngine raised Isotechnika Pharma from a sell rating to a hold rating in a research report on Friday, February 2nd. Canaccord Genuity set a $11.00 target price on Isotechnika Pharma and gave the stock a buy rating in a research report on Friday, November 17th. Finally, Royal Bank of Canada assumed coverage on Isotechnika Pharma in a research report on Thursday, February 8th. They set an outperform rating and a $9.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $10.93.
Shares of NASDAQ:AUPH traded down $0.05 during midday trading on Friday, hitting $5.15. 423,534 shares of the stock were exchanged, compared to its average volume of 714,988. Isotechnika Pharma has a 52-week low of $4.41 and a 52-week high of $8.19. The firm has a market cap of $432.87, a price-to-earnings ratio of -5.60 and a beta of 2.26.
Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.10. Isotechnika Pharma had a negative return on equity of 17.54% and a negative net margin of 16,855.24%. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. During the same period last year, the company earned ($0.11) earnings per share. The business’s revenue was up .0% compared to the same quarter last year. sell-side analysts anticipate that Isotechnika Pharma will post -0.7 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its holdings in Isotechnika Pharma by 33.2% during the fourth quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock valued at $7,540,000 after purchasing an additional 414,400 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Isotechnika Pharma by 36.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock valued at $5,411,000 after acquiring an additional 319,639 shares during the last quarter. BlackRock Inc. bought a new position in shares of Isotechnika Pharma in the fourth quarter valued at approximately $3,261,000. Alyeska Investment Group L.P. raised its stake in shares of Isotechnika Pharma by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after acquiring an additional 12,171 shares during the last quarter. Finally, Hudson Bay Capital Management LP raised its stake in shares of Isotechnika Pharma by 20.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $2,039,000 after acquiring an additional 75,000 shares during the last quarter. 28.50% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Isotechnika Pharma (NASDAQ:AUPH) Stock Rating Reaffirmed by Seaport Global Securities” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/09/aurinia-pharmaceuticals-auph-given-buy-rating-at-seaport-global-securities.html.
Isotechnika Pharma Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.